Johnson & Johnson has axed two CAR-T programs targeting B-cell lymphoma—discontinuing JNJ-9530 and the CD19/CD20 bispecific JNJ-4496—citing an evolving treatment landscape and J&J portfolio priorities. The programs were at early clinical stages, and J&J said it will continue supporting patients enrolled under existing protocols. The decision follows J&J’s earlier optimism around the programs, including disclosed complete response rates from phase 1b work on JNJ-4496. However, J&J’s shift removes a potential competitive pressure point in a market that already features multiple CAR-T and bispecific approaches. For the CAR-T ecosystem, the exit highlights how quickly the treatment narrative can change once new approvals accumulate and when portfolio strategy turns toward scale and Phase 3 readiness.